51
|
Jankowski M, Spużak J, Kubiak K, Glińska-Suchocka K, Biernat M. Detection of Helicobacter spp. in the saliva of dogs with gastritis. Pol J Vet Sci 2016; 19:133-40. [DOI: 10.1515/pjvs-2016-0017] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
AbstractThe aim of this study was to identify the species and determine the prevalence of gastric Helicobacter in the saliva of dogs with gastritis. The study was carried out on 30 dogs of different breeds, genders and ages, which were diagnosed with gastritis. The nested-PCR method was used to detect Helicobacter spp. in saliva. Helicobacter bacteria were found in the saliva samples of 23 (76.6%) dogs. Helicobacter heilmannii was the most commonly detected species of gastric Helicobacter spp. in canine saliva, and was found in 22 (73.3%) cases. The results indicate that gastric Helicobacter spp. occurs relatively frequently in dogs with gastritis. Moreover, the saliva of dogs with gastritis may be a source of Helicobacter spp. infection for humans and other animals. However, further studies are needed to confirm this finding as the PCR method does not distinguish active from inactive infections.
Collapse
|
52
|
Bąkowska J, Kubiak K, Spużak J, Glińska-Suchocka K, Jankowski M, Borusewicz P, Grzegory M, Sołtysiak Z, Orlowska A. Polioencephalomalacia in Goats: A Clinical Case Report. J Comp Pathol 2016. [DOI: 10.1016/j.jcpa.2015.10.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
53
|
Rybicki BA, Kryvenko ON, Wang Y, Jankowski M, Trudeau S, Chitale DA, Gupta NS, Rundle A, Tang D. Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer. Prostate Cancer Prostatic Dis 2015; 19:145-50. [PMID: 26620738 DOI: 10.1038/pcan.2015.54] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Revised: 09/04/2015] [Accepted: 09/18/2015] [Indexed: 11/09/2022]
Abstract
BACKGROUND Epidemiologic studies, primarily done in white men, suggest that a history of clinically-diagnosed prostatitis increases prostate cancer risk, but that histological prostate inflammation decreases risk. The relationship between a clinical history of prostatitis and histologic inflammation in terms of how these two manifestations of prostatic inflammation jointly contribute to prostate cancer risk and whether racial differences exist in this relationship is uncertain. METHODS Using a nested design within a cohort of men with benign prostate tissue specimens, we analyzed the data on both clinically-diagnosed prostatitis (NIH categories I-III) and histological inflammation in 574 prostate cancer case-control pairs (345 white, 229 African American). RESULTS Clinical prostatitis was not associated with increased prostate cancer risk in the full sample, but showed a suggestive inverse association with prostate cancer in African Americans (odds ratio (OR)=0.47; 95% confidence interval (CI)=0.27-0.81). In whites, clinical prostatitis increased risk by 40%, but was only associated with a significant increased prostate cancer risk in the absence of evidence of histological inflammation (OR=3.56; 95% CI=1.15-10.99). Moreover, PSA velocity (P=0.008) and frequency of PSA testing (P=0.003) were significant modifiers of risk. Clinical prostatitis increased risk of prostate cancer almost three-fold (OR=2.97; 95% CI=1.40-6.30) in white men with low PSA velocity and about twofold in white men with more frequent PSA testing (OR=1.91; 95% CI=1.09-3.35). CONCLUSIONS In our cohort of men with benign prostate specimens, race, and histological inflammation were important cofactors in the relationship between clinical prostatitis and prostate cancer. Clinical prostatitis was associated with a slightly decreased risk for prostate cancer in African American men. In white men, the relationship between clinical prostatitis and prostate cancer risk was modified by histological prostatic inflammation, PSA velocity, and frequency of PSA testing-suggesting a complex interplay between these indications of prostatic inflammation and prostate cancer detection.
Collapse
Affiliation(s)
- B A Rybicki
- Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA
| | - O N Kryvenko
- Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA.,Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Y Wang
- Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA
| | - M Jankowski
- Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA
| | - S Trudeau
- Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA
| | - D A Chitale
- Department of Pathology, Henry Ford Health System, Detroit, MI, USA
| | - N S Gupta
- Department of Pathology, Henry Ford Health System, Detroit, MI, USA
| | - A Rundle
- Department of Epidemiology, Columbia University, New York, NY, USA
| | - D Tang
- Department of Environmental Health Sciences, Columbia University, New York, NY, USA
| |
Collapse
|
54
|
Jankowski M. Aspects of nursing regarding haemofiltration. Contrib Nephrol 2015; 32:222-4. [PMID: 7128160 DOI: 10.1159/000406927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
55
|
Jankowski M, Las - Jankowska M, Bala D, Tkaczynski K, Tarczynski M, Wiczolek A, Zegarski W. 279. Treatment outcomes following extended resections due to advanced rectal cancer. Eur J Surg Oncol 2014. [DOI: 10.1016/j.ejso.2014.08.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
56
|
Nowikiewicz T, Srutek E, Jankowski M, Las-Jankowska M, Klag M, Kozak D, Glowacka I, Zegarski W. Management and results of treatment of breast cancer patients having sentinel lymph node micrometastases. Neoplasma 2014; 61:299-304. [PMID: 24824931 DOI: 10.4149/neo_2014_038] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
According to current therapeutic guidelines, finding micrometastases in the sentinel node (SLN) of a patient with non-advanced breast cancer is not an absolute indication for adjuvant axillary lymph node dissection (ALND). This work presents our experiences regarding this clinical problem. 1071 breast cancer patients were referred for sentinel node biopsy between January 2004 and December 2011. Metastases were found in 245 of the removed lymph nodes. In 49 patients lymph node changes turned out to be micrometastases or isolated tumor cells (ITC). ALND was performed in 38 cases of sentinel node micrometastases or ICTs. In three patients involvement of other axillary lymph nodes was found in the studied tissue material (7.9% vs. 37.9% for metastases >2mm). The remaining patients with micrometastases in the SLN (11/49) were treated conservatively. No local axillary recurrences or neoplastic metastases were found in this group of patients with SLN micrometastases. Mean follow-up period in patients who had undergone ALND was 18.0 months (4 to 60 months) and 21.4 months (9-40 months) in patients without ALND. Non-radical surgical treatment in the presence of SLN micrometastases in patients with non-advanced breast cancer does not lead to therapeutic failure (local axillary recurrences, distant metastases). Obtaining favorable outcomes of conservative treatment in the analyzed group of patients does not require additional modification of the adjuvant therapy.
Collapse
|
57
|
Xu H, Huang X, Riserus U, Cederholm T, Lindholm B, Arnlov J, Carrero JJ, Leiba A, Vivante A, Bulednikov Y, Golan E, Skorecki K, Shohat T, Mjoen G, Zannad F, Jardine A, Schmieder R, Fellstrom B, Holdaas H, Zager P, Miskulin D, Gassman J, Kendrick C, Ploth D, Jhamb M, Jankowski V, Schulz A, Mischak H, Zidek W, Jankowski J, Lee YK, Cho A, Kim JK, Choi MJ, Kim SJ, Yoon JW, Koo JR, Kim HJ, Noh JW, Itano S, Satoh M, Kidokoro K, Sasaki T, Kashihara N, Koutroumpas G, Sarafidis P, Georgianos P, Karpetas A, Protogerou A, Syrganis C, Malindretos P, Raptopoulou K, Panagoutsos S, Pasadakis P, Zager P, Miskulin D, Gassman J, Kendrick C, Jhamb M, Ploth D, Vink EE, De Boer A, Verloop WL, Spiering W, Voskuil M, Vonken EJ, Hoogduin JM, Leiner T, Bots ML, Blankestijn PJ, Sarafidis PA, Karpetas AV, Georgianos PI, Bikos A, Sklavenitis-Pistofidis R, Tzimou R, Raptis V, Vakianis P, Tersi M, Liakopoulos V, Lasaridis AN, Protogerou A, Ribeiro S, Fernandes J, Garrido P, Sereno J, Vala H, Bronze Da Rocha E, Belo L, Costa E, Reis F, Santos-Silva A, Kalaitzidis R, Skapinakis P, Karathanos V, Karasavvidou D, Katatsis G, Pappas K, Hatzidakis S, Siamopoulos K, Margulis F, Sabbatiello R, Castro C, Ramallo S, Martinez M, Schiavelli R, Ganem D, Nakhoul F, Roth A, Farber E, Kim CS, Kim HY, Kang YU, Choi JS, Bae EH, Ma SK, Kim SW, Koutroumpas G, Sarafidis P, Georgianos P, Karpetas A, Protogerou A, Malindretos P, Syrganis C, Tzanis G, Panagoutsos S, Pasadakis P, Jankowski M, Kasztan M, Kowalski R, Piwkowska A, Rogacka D, Szczepa Ska-Konkel M, Angielski S, Evangelou D, Naka K, Kalaitzidis R, Lakkas L, Bechlioulis A, Gkirdis I, Nakas G, Zarzoulas F, Kotsia A, Balafa O, Tzeltzes G, Pappas K, Katsouras C, Dounousi E, Michalis L, Siamopoulos K, Maciorkowska D, Zbroch E, Koc-Zorawska E, Malyszko J, Karabay Bayazit A, Yuksekkaya I, Aynaci S, Anarat A, Nakai K, Fujii H, Ishida R, Utaka C, Awata R, Goto S, Ito J, Nishi S, Elsurer R, Afsar B, Lepar Z, Radulescu D, David C, Peride I, Niculae A, Checherita IA, Ciocalteu A, Sungur CI, Kanbay M, Siriopol D, Nistor I, Elcioglu OC, Telci O, Johnson R, Covic A, Vettoretti S, Gallazzi E, Meazza R, Gagliardi V, Villarini A, Alfieri CM, Floreani R, Messa P, Vettoretti S, Alfieri CM, Gallazzi E, Gagliardi V, Villarini A, Meazza R, Floreani R, Messa P, Kotovskaya Y, Villevalde S, Kobalava Z, Circiumaru A, Rusu E, Zilisteanu D, Atasie T, Cirstea F, Ecobici M, Voiculescu M, Rosca M, Tanase C, Baoti I, Vidjak V, Prka in I, Bulum T, Arslan E, Sarlak H, Cakar M, Demirbas S, Akhan M, Kurt O, Balta S, Yesilkaya S, Bulucu F, Chan CK, Lin YH, Wu VC, Wu KD, De Beus E, Bots ML, Van Zuilen AD, Wetzels JF, Blankestijn PJ, Mohaupt M, Straessle K, Baumann M, Raio L, Sirbek D, Nascimento MA, Mouro MG, Punaro GR, Mello MT, Tufik S, Higa EMS. HYPERTENSION. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
58
|
Chan JSD, Abdo S, Ghosh A, Alquier T, Chenier I, Filep JG, Ingelfinger JR, Zhang SL, Ross EA, Willenberg BJ, Oca-Cossio J, Clapp WL, Terada N, Abrahamson DR, Ellison GW, Matthews CE, Batich CD, Ihoriya C, Satoh M, Sasaki T, Kashihara N, Piwkowska A, Rogacka D, Angielski S, Jankowski M, Pontrelli P, Conserva F, Papale M, Accetturo M, Gigante M, Vocino G, Dipalma AM, Grandaliano G, Di Paolo S, Gesualdo L, Franzen S, Pihl L, Khan N, Gustafsson H, Palm F, Koszegi S, Hodrea J, Lenart L, Hosszu A, Wagner L, Vannay A, Tulassay T, Szabo A, Fekete A, Aoki R, Sekine F, Kikuchi K, Miyazaki S, Yamashita Y, Itoh Y, Kolling M, Park JK, Haller H, Thum T, Lorenzen J, Hirayama A, Yoh K, Ueda A, Itoh H, Owada S, Kokeny G, Szabo L, Fazekas K, Rosivall L, Mozes MM, Kim Y, Koh ES, Lim JH, Kim MY, Chang YS, Park CW, Kim Y, Kim HW, Kim MY, Lim JH, Chang YS, Park CW, Shin BC, Kim HL, Chung JH, Chan JS, Wu TC, Chen JW, Rogacka D, Piwkowska A, Angielski S, Jankowski M, Clotet S, Soler MJ, Rebull M, Pascual J, Riera M, Patinha D, Afonso J, Sousa T, Morato M, Albino-Teixeira A, Kim H, Min HS, Kang MJ, Kim JE, Lee JE, Kang YS, Cha DR, Jo YI, Seo EH, Kim JD, Lee SH, Jorge L, Silva KAS, Luiz RS, Rampaso RR, Lima W, Cunha TS, Schor N, Lee HJ, Park JY, Kim SK, Moon JY, Lee SH, Ihm CG, Lee TW, Jeong KH, Moon JY, Kim S, Park JY, Kim SY, Kim YG, Jeong KH, Lee SH, Ihm CG, Marques C, Mega C, Goncalves A, Rodrigues-Santos P, Teixeira-Lemos E, Teixeira F, Fontes Ribeiro C, Reis F, Fernandes R, Sutariya BK, Badgujar LB, Kshtriya AA, Saraf MN, Chiu CH, Lee WC, Chau YY, Lee LC, Lee CT, Chen JB, Dahan I, Nakhoul F, Thawho N, Ben-Itzhaq O, Levy AP, Conserva F, Pontrelli P, Accetturo M, Cordisco G, Fiorentino L, Federici M, Grandaliano G, Di Paolo S, Gesualdo L, Wystrychowski G, Havel PJ, Graham JL, Zukowska-Szczechowska E, Obuchowicz E, Psurek A, Grzeszczak W, Wystrychowski A, Clotet S, Soler MJ, Rebull M, Gimeno J, Pascual J, Riera M, Almeida BZD, Seraphim DCC, Punaro G, Nascimento M, Mouro M, Lanzoni VP, Lopes GS, Higa EMS, Roca-Ho H, Riera M, Marquez E, Pascual J, Soler MJ. DIABETES EXPERIMENTAL. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
59
|
Abstract
Studies of body volume expansion have indicated that lesions of the anteroventral third ventricle and median eminence block the release of atrial natriuretic peptide (ANP) into the circulation. Detailed analysis of the lesions showed that activation of oxytocin (OT)-ergic neurons is responsible for ANP release, and it has become clear that activation of neuronal circuitry elicits OT secretion into the circulation, activating atrial OT receptors and ANP release from the heart. Subsequently, we have uncovered the entire functional OT system in the rat and the human heart. An abundance of OT has been observed in the early development of the fetal heart, and the capacity of OT to generate cardiomyocytes (CMs) has been demonstrated in various types of stem cells. OT treatment of mesenchymal stem cells stimulates paracrine factors beneficial for cardioprotection. Cardiovascular actions of OT include: i) lowering blood pressure, ii) negative inotropic and chronotropic effects, iii) parasympathetic neuromodulation, iv) vasodilatation, v) anti-inflammatory activity, vi) antioxidant activity, and vii) metabolic effects. OT actions are mediated by nitric oxide and ANP. The beneficial actions of OT may include the increase in glucose uptake by CMs and stem cells, reduction in CM hypertrophy, oxidative stress, and mitochondrial protection of several cell types. In experimentally induced myocardial infarction in rats, continuous in vivo OT delivery improves cardiac healing and cardiac work, reduces inflammation, and stimulates angiogenesis. Because OT plays anti-inflammatory and cardioprotective roles and improves vascular and metabolic functions, it demonstrates potential for therapeutic use in various pathologic conditions.
Collapse
Affiliation(s)
- J Gutkowska
- Laboratory of Cardiovascular Biochemistry, Department of Medicine, Faculty of Medicine, University of Montreal, CHUM Research Centre, Montreal, Quebec, Canada
| | - M Jankowski
- Laboratory of Cardiovascular Biochemistry, Department of Medicine, Faculty of Medicine, University of Montreal, CHUM Research Centre, Montreal, Quebec, Canada
| | - J Antunes-Rodrigues
- Departamento de Fisiologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brasil
| |
Collapse
|
60
|
Alba A, Agoritsas T, Jankowski M, Couvoisier D, Walter S, Guyatt G, Ross H. Risk Prediction Models for Mortality in Ambulatory Heart Failure Patients: A Systematic Review. Can J Cardiol 2013. [DOI: 10.1016/j.cjca.2013.07.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
61
|
Alba AC, Agoritsas T, Jankowski M, Courvoisier D, Walter SD, Guyatt GH, Ross HJ. Risk Prediction Models for Mortality in Ambulatory Patients With Heart Failure. Circ Heart Fail 2013; 6:881-9. [DOI: 10.1161/circheartfailure.112.000043] [Citation(s) in RCA: 125] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Ana C. Alba
- From the Heart Failure and Transplantation Program, Toronto General Hospital, University Health Network, Ontario, Canada (A.C.A., H.J.R.); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (T.A., S.D.W., G.H.G.); Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland (M.J.); and Center for Health Behavior Monitoring and Intervention, University of Rhode Island, Kingston, RI (D.C.)
| | - Thomas Agoritsas
- From the Heart Failure and Transplantation Program, Toronto General Hospital, University Health Network, Ontario, Canada (A.C.A., H.J.R.); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (T.A., S.D.W., G.H.G.); Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland (M.J.); and Center for Health Behavior Monitoring and Intervention, University of Rhode Island, Kingston, RI (D.C.)
| | - Milosz Jankowski
- From the Heart Failure and Transplantation Program, Toronto General Hospital, University Health Network, Ontario, Canada (A.C.A., H.J.R.); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (T.A., S.D.W., G.H.G.); Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland (M.J.); and Center for Health Behavior Monitoring and Intervention, University of Rhode Island, Kingston, RI (D.C.)
| | - Delphine Courvoisier
- From the Heart Failure and Transplantation Program, Toronto General Hospital, University Health Network, Ontario, Canada (A.C.A., H.J.R.); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (T.A., S.D.W., G.H.G.); Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland (M.J.); and Center for Health Behavior Monitoring and Intervention, University of Rhode Island, Kingston, RI (D.C.)
| | - Stephen D. Walter
- From the Heart Failure and Transplantation Program, Toronto General Hospital, University Health Network, Ontario, Canada (A.C.A., H.J.R.); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (T.A., S.D.W., G.H.G.); Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland (M.J.); and Center for Health Behavior Monitoring and Intervention, University of Rhode Island, Kingston, RI (D.C.)
| | - Gordon H. Guyatt
- From the Heart Failure and Transplantation Program, Toronto General Hospital, University Health Network, Ontario, Canada (A.C.A., H.J.R.); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (T.A., S.D.W., G.H.G.); Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland (M.J.); and Center for Health Behavior Monitoring and Intervention, University of Rhode Island, Kingston, RI (D.C.)
| | - Heather J. Ross
- From the Heart Failure and Transplantation Program, Toronto General Hospital, University Health Network, Ontario, Canada (A.C.A., H.J.R.); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (T.A., S.D.W., G.H.G.); Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland (M.J.); and Center for Health Behavior Monitoring and Intervention, University of Rhode Island, Kingston, RI (D.C.)
| |
Collapse
|
62
|
Blanco-Gozalo V, Blazquez-Medela A, Garcia-Sanchez O, Quiros Y, Montero M, Martinez-Salgado C, Lopez-Hernandez F, Lopez-Novoa J, Yao L, Qing Z, Hua X, Min F, Fei M, Ning W, Cantaluppi V, Figliolini F, Delena M, Beltramo S, Medica D, Tetta C, Segoloni G, Biancone L, Camussi G, Cunha JS, Ferreira VM, Naves MA, Boim MA, Zitman-Gal T, Golan E, Green J, Pasmanik-Chor M, Bernheim J, Benchetrit S, Riera M, Clotet S, Pascual J, Soler M, Nakai K, Fujii H, Kono K, Goto S, Hirata M, Shinohara M, Fukagawa M, Nishi S, Fan Q, Du S, Jiang Y, Wang L, Fang L, Radovits T, Mozes MM, Rosivall L, Kokeny G, Aoki R, Tateoka R, Sekine F, Kikuchi K, Yamashita Y, Itoh Y, Cappuccino L, Garibotto G, D'Amato E, Villaggio B, Gianiorio F, Mij M, Viazzi F, Salvidio G, Verzola D, Piwkowska A, Rogacka D, Audzeyenka I, Kasztan M, Angielski S, Jankowski M, Gaber EW, El-Attar HA, Liu J, Zhang W, He Y, Rogacka D, Piwkowska A, Audzeyenka I, Angielski S, Jankowski M, Macsai E, Takats Z, Derzbach L, Korner A, Vasarhelyi B, Huang MS, Bo H, Liu F, Fu P, Tsotakos NE, Tsilibary EC, Drossopoulou GI, Thawho N, Farid N, Peleg A, Levy A, Nakhoul N, Lenghel AR, Borza G, Catoi C, Bondor CI, Muresan A, Kacso IM, Song JS, Song JH, Ahn SH, Choi BS, Hong YA, Kim MY, Lim JH, Yang KS, Chung S, Shin SJ, Kim HW, Chang YS, Kim YS, Park CW, Takayanagi K, Hasegawa H, Shimizu T, Ikari A, Noiri C, Iwashita T, Tayama Y, Asakura J, Anzai N, Kanozawa K, Kato H, Mitarai T, Huang M, Bo H, Liu F, Fu P, Ashour RH, Fouda AEMM, Saad MA, El-Banna FM, Moustafa FA, Fouda MI, Sanchez-Nino MD, Sanz AB, Poveda J, Saleem M, Mathieson P, Ruiz-Ortega M, Selgas R, Egido J, Ortiz A, Clotet S, Soler MJ, Rebull M, Pascual J, Riera M, Marquez E, Riera M, Pascual J, Soler MJ, Asakura J, Hasegawa H, Takayanagi K, Tayama Y, Shimizu T, Iwashita T, Okazaki S, Kogure Y, Sano T, Hatano M, Kanozawa K, Kato H, Mitarai T, Kreft E, Kowalski R, Kasztan M, Jankowski M, Szczepansk-Konkel M, Fan Q, Liu X, Yang G, Jiang Y, Wang L, Osman NA, NasrAllah MM, Kamal MM, Ahmed AI, Fekih-Mrissa N, Mrad M, Baffoun A, Sayeh A, Hmida J, Gritli N, Galchinskaya V, Topchii I, Semenovykh P, Yefimova N, Zheng D, Hu D, Li X, Peng AI, Olea-Herrero N, Arenas M, Munoz-Moreno C, Moreno-Gomez-Toledano R, Gonzalez-Santander M, Arribas I, Bosch R. Diabetes - experimental models. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
63
|
Kanlaya R, Sintiprungrat K, Thongboonkerd V, Torremade N, Bindels R, Hoenderop J, Fernandez E, Dusso A, Valdivielso JM, Krueger T, Boor P, Schafer C, Westenfeld R, Brandenburg V, Schlieper G, Jahnen-Dechent W, Ketteler M, Jee W, Li X, Richards B, Floege J, Goncalves JG, Canale D, de Braganca AC, Shimizu MHM, Moyses RMA, Andrade L, Seguro AC, Volpini RA, Romoli S, Migliorini A, Anders HJ, Eskova O, Neprintseva N, Tchebotareva N, Bobkova I, Kozlovskaya L, Simic I, Tabatabaeifar M, Wlodkowski T, Denc H, Mollet G, Antignac C, Schaefer F, Ekaterina IA, Giardino L, Rastaldi MP, Van den Heuvel L, Levtchenko E, Okina C, Okamoto T, Kamata M, Murano J, Kobayashi K, Takeuchi K, Kamata F, Sakai T, Naito S, Aoyama T, Sano T, Takeuchi Y, Kamata K, Thomasova D, Bruns HA, Liapis H, Anders HJ, Iwashita T, Hasegawa H, Takayanagi K, Shimizu T, Asakura J, Okazaki S, Kogure Y, Hatano M, Hara H, Inamura M, Iwanaga M, Mitani T, Mitarai T, Savin VJ, Sharma M, Wei C, Reiser J, McCarthy ET, Sharma R, Gauchat JF, Eneman B, Freson K, Van den Heuvel L, Van Geet C, Levtchenko E, Choi DE, Jeong JY, Chang YK, Na KR, Lee KW, Shin YT, Ni HF, Chen JF, Zhang MH, Pan MM, Liu BC, Lee KW, Jeong JY, Choi DE, Chang YK, Kim SS, Na KR, Shin YT, Suzuki T, Iyoda M, Matsumoto K, Shindo-Hirai Y, Kuno Y, Wada Y, Yamamoto Y, Shibata T, Akizawa T, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Ehling J, Babickova J, Gremse F, Kiessling F, Floege J, Lammers T, Boor P, Lech M, Gunthner R, Lorenz G, Ryu M, Grobmayr R, Susanti H, Kobayashi KS, Flavell RA, Anders HJ, Rayego-Mateos S, Morgado J, Sanz AB, Eguchi S, Pato J, Keri G, Egido J, Ortiz A, Ruiz-Ortega M, Leduc M, Geerts L, Grouix B, Sarra-Bournet F, Felton A, Gervais L, Abbott S, Duceppe JS, Zacharie B, Penney C, Laurin P, Gagnon L, Detsika MG, Duann P, Lianos EA, Leong KI, Chiang CK, Yang CC, Wu CT, Chen LP, Hung KY, Liu SH, Carvalho FF, Teixeira VP, Almeida WS, Schor N, Small DM, Bennett NC, Coombes J, Johnson DW, Gobe GC, Montero N, Prada A, Riera M, Orfila M, Pascual J, Rodriguez E, Barrios C, Kokeny G, Fazekas K, Rosivall L, Mozes MM, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Hornigold N, Hughes J, Mooney A, Benardeau A, Riboulet W, Vandjour A, Jacobsen B, Apfel C, Conde-Knape K, Grouix B, Felton A, Sarra-Bournet F, Leduc M, Geerts L, Gervais L, Abbott S, Bienvenu JF, Duceppe JS, Zacharie B, Penney C, Laurin P, Gagnon L, Tanaka T, Yamaguchi J, Nangaku M, Niwa T, Bolati D, Shimizu H, Yisireyili M, Nishijima F, Brocca A, Virzi G, de Cal M, Ronco C, Priante G, Musacchio E, Valvason C, Sartori L, Piccoli A, Baggio B, Boor P, Perkuhn M, Weibrecht M, Zok S, Martin IV, Schoth F, Ostendorf T, Kuhl C, Floege J, Karabaeva A, Essaian A, Beresneva O, Parastaeva M, Kayukov I, Smirnov A, Audzeyenka I, Kasztan M, Piwkowska A, Rogacka D, Angielski S, Jankowski M, Bockmeyer CL, Kokowicz K, Agustian PA, Zell S, Wittig J, Becker JU, Nishizono R, Venkatareddy MP, Chowdhury MA, Wang SQ, Fukuda A, Wickman LT, Yang Y, Wiggins RC, Fazio MR, Donato V, Lucisano S, Cernaro V, Lupica R, Trimboli D, Montalto G, Aloisi C, Mazzeo AT, Buemi M, Gawrys O, Olszynski KH, Kuczeriszka M, Gawarecka K, Swiezewska E, Chmielewski M, Masnyk M, Rafalowska J, Kompanowska-Jezierska E, Lee WC, Chau YY, Lee LC, Chiu CH, Lee CT, Chen JB, Kim WK, Shin SJ. Experimental models of CKD. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
64
|
Silver B, Miller D, Jankowski M, Murshed N, Garcia P, Penstone P, Straub M, Logan SP, Sinha A, Morris DC, Katramados A, Russman AN, Mitsias PD, Schultz LR. Urine toxicology screening in an urban stroke and TIA population. Neurology 2013; 80:1702-9. [DOI: 10.1212/wnl.0b013e318293e2fe] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
65
|
Alba A, Agoritsas T, Jankowski M, Courvoisier D, Walter S, Guyatt G, Ross H. Risk Prediction Models for Mortality in Ambulatory Heart Failure Patients: A Systematic Review. J Heart Lung Transplant 2013. [DOI: 10.1016/j.healun.2013.01.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
66
|
Busse JW, Ebrahim S, Connell G, Coomes EA, Bruno P, Malik K, Torrance D, Ngo T, Kirmayr K, Avrahami D, Riva JJ, Struijs P, Brunarski D, Burnie SJ, LeBlanc F, Steenstra IA, Mahood Q, Thorlund K, Montori VM, Sivarajah V, Alexander P, Jankowski M, Lesniak W, Faulhaber M, Bała MM, Schandelmaier S, Guyatt GH. Systematic review and network meta-analysis of interventions for fibromyalgia: a protocol. Syst Rev 2013; 2:18. [PMID: 23497523 PMCID: PMC3610251 DOI: 10.1186/2046-4053-2-18] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2013] [Accepted: 02/22/2013] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Fibromyalgia is associated with substantial socioeconomic loss and, despite considerable research including numerous randomized controlled trials (RCTs) and systematic reviews, there exists uncertainty regarding what treatments are effective. No review has evaluated all interventional studies for fibromyalgia, which limits attempts to make inferences regarding the relative effectiveness of treatments. METHODS/DESIGN We will conduct a network meta-analysis of all RCTs evaluating therapies for fibromyalgia to determine which therapies show evidence of effectiveness, and the relative effectiveness of these treatments. We will acquire eligible studies through a systematic search of CINAHL, EMBASE, MEDLINE, AMED, HealthSTAR, PsychINFO, PapersFirst, ProceedingsFirst, and the Cochrane Central Registry of Controlled Trials. Eligible studies will randomly allocate patients presenting with fibromyalgia or a related condition to an intervention or a control. Teams of reviewers will, independently and in duplicate, screen titles and abstracts and complete full text reviews to determine eligibility, and subsequently perform data abstraction and assess risk of bias of eligible trials. We will conduct meta-analyses to establish the effect of all reported therapies on patient-important outcomes when possible. To assess relative effects of treatments, we will construct a random effects model within the Bayesian framework using Markov chain Monte Carlo methods. DISCUSSION Our review will be the first to evaluate all treatments for fibromyalgia, provide relative effectiveness of treatments, and prioritize patient-important outcomes with a focus on functional gains. Our review will facilitate evidence-based management of patients with fibromyalgia, identify key areas for future research, and provide a framework for conducting large systematic reviews involving indirect comparisons.
Collapse
Affiliation(s)
- Jason W Busse
- Department of Anesthesia, McMaster University, 1200 Main Street West, Hamilton, Ontario, L8S 4K1, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
67
|
Noiseux N, Borie M, Desnoyers A, Menaouar A, Stevens L, Mansour S, Danalache B, Roy D, Jankowski M, Gutkowska J. 531 Improving Stem Cell Therapeutic Potential by Oxytocin Preconditioning. Can J Cardiol 2012. [DOI: 10.1016/j.cjca.2012.07.484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
68
|
Abstract
Traditionally associated with female reproduction, oxytocin (OT) was revisited recently and was revealed to have several new roles in the cardiovascular system. Functional OT receptors have been discovered in the rat and human heart, as well as in vascular beds. The cardiovascular activities of OT include: (i) lowering blood pressure; (ii) negative cardiac inotropy and chronotropy; (iii) parasympathetic neuromodulation; (iv) vasodilatation; (v) anti-inflammatory; (vi) antioxidative; and (vii) metabolic effects. These outcomes are mediated, at least in part, by stimulating cardioprotective mediators, such as nitric oxide and atrial natriuretic peptide. OT and its extended form OT-Gly-Lys-Arg have been shown to be abundant in the foetal mouse heart. OT has the capacity to generate cardiomyocytes from various types of stem cells, including the cardiac side population. Mesenchymal cells transfected with OT-Gly-Lys-Arg, or preconditioned with OT, are resistant to apoptosis and express endothelial cell markers. OT increases glucose uptake in cultured cardiomyocytes from newborn and adult rats, in normal, hypoxic and even insulin resistance conditions. In rats with experimentally-induced myocardial infarction, continuous in vivo OT delivery improves the cardiac healing process, as well as cardiac work, reduces inflammation and stimulates angiogenesis. Therefore, in pathological conditions, OT exerts anti-inflammatory and cardioprotective properties, and improves vascular and metabolic functions. Thus, OT has potential for therapeutic use.
Collapse
Affiliation(s)
- J Gutkowska
- Laboratory of Cardiovascular Biochemistry, Centre de recherche, Centre hospitalier de l'Université de Montréal (CRCHUM) - Hôtel-Dieu and Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.
| | | |
Collapse
|
69
|
Silver M, Rusk A, Phillips B, Beck E, Jankowski M, Philibert J, Hahn K, Hershey E, McKeegan E, Bauch J, Krivoshik A, Khanna C. Evaluation of the Oral Antimitotic Agent (ABT-751) in Dogs with Lymphoma. J Vet Intern Med 2012; 26:349-54. [DOI: 10.1111/j.1939-1676.2012.00892.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2011] [Revised: 10/12/2011] [Accepted: 01/04/2012] [Indexed: 11/29/2022] Open
Affiliation(s)
- M. Silver
- Animal Clinical Investigation; LLC and The Oncology Service; Washington; DC
| | - A. Rusk
- Animal Clinical Investigation; LLC and The Oncology Service; Washington; DC
| | - B. Phillips
- Veterinary Specialty Hospital; San Diego; CA
| | - E. Beck
- Regional Veterinary Referral Center; Springfield; VA
| | - M. Jankowski
- Southpaws Veterinary Referral Center; Fairfax; VA
| | - J. Philibert
- New England Veterinary Oncology Group; Waltham; MA
| | - K. Hahn
- Hill's Pet Nutrition, Inc; Topeka; KS
| | - E. Hershey
- Arizona Veterinary Specialists; Gilbert; AZ
| | | | | | | | - C. Khanna
- Animal Clinical Investigation; LLC and The Oncology Service; Washington; DC
| |
Collapse
|
70
|
MacLean S, Mulla S, Akl EA, Jankowski M, Vandvik PO, Ebrahim S, McLeod S, Bhatnagar N, Guyatt GH. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e1S-e23S. [PMID: 22315262 PMCID: PMC3278050 DOI: 10.1378/chest.11-2290] [Citation(s) in RCA: 186] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/31/2011] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Development of clinical practice guidelines involves making trade-offs between desirable and undesirable consequences of alternative management strategies. Although the relative value of health states to patients should provide the basis for these trade-offs, few guidelines have systematically summarized the relevant evidence. We conducted a systematic review relating to values and preferences of patients considering antithrombotic therapy. METHODS We included studies examining patient preferences for alternative approaches to antithrombotic prophylaxis and studies that examined, in the context of antithrombotic prophylaxis or treatment, how patients value alternative health states and experiences with treatment. We conducted a systematic search and compiled structured summaries of the results. Steps in the process that involved judgment were conducted in duplicate. RESULTS We identified 48 eligible studies. Sixteen dealt with atrial fibrillation, five with VTE, four with stroke or myocardial infarction prophylaxis, six with thrombolysis in acute stroke or myocardial infarction, and 17 with burden of antithrombotic treatment. CONCLUSION Patient values and preferences regarding thromboprophylaxis treatment appear to be highly variable. Participant responses may depend on their prior experience with the treatments or health outcomes considered as well as on the methods used for preference elicitation. It should be standard for clinical practice guidelines to conduct systematic reviews of patient values and preferences in the specific content area.
Collapse
Affiliation(s)
- Samantha MacLean
- Department of Biostatistics and Clinical Epidemiology, McMaster University, Hamilton, ON, Canada.
| | - Sohail Mulla
- Department of Biostatistics and Clinical Epidemiology, McMaster University, Hamilton, ON, Canada
| | - Elie A Akl
- Department of Biostatistics and Clinical Epidemiology, McMaster University, Hamilton, ON, Canada; Department of Medicine, State University of New York at Buffalo, Buffalo, NY
| | - Milosz Jankowski
- Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
| | - Per Olav Vandvik
- Norwegian Knowledge Centre for the Health Services and Department of Medicine Gjøvik, Innlandet Hospital Trust, Gjøvik, Norway
| | - Shanil Ebrahim
- Department of Biostatistics and Clinical Epidemiology, McMaster University, Hamilton, ON, Canada
| | - Shelley McLeod
- Division of Emergency Medicine, Department of Medicine, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada
| | - Neera Bhatnagar
- Department of Health Sciences Library, McMaster University, Hamilton, ON, Canada
| | - Gordon H Guyatt
- Department of Biostatistics and Clinical Epidemiology, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
71
|
Tatara M, Krupski W, Jankowski M, Zduńczyk Z, Jankowski J, Studziński T. Effects of dietary calcium content and vitamin D source on skeletal properties in growing turkeys. Br Poult Sci 2011; 52:718-29. [DOI: 10.1080/00071668.2011.631984] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
72
|
Jankowski M, Szamocka E, Kowalski R, Angielski S, Szczepańska-Konkel M. The effects of P2X receptor agonists on renal sodium and water excretion in anaesthetized rats. Acta Physiol (Oxf) 2011; 202:193-201. [PMID: 21392268 DOI: 10.1111/j.1748-1716.2011.02276.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
AIM To investigate in vivo effects of P2X receptor activation on sodium and water excretion in urine. METHODS The clearance experiments were carried out in anaesthetized rats during intravenous infusion (2 μmol kg(-1) + 20 nmol (kg min)(-1) , v = 40 μL min(-1)) of P2X receptors agonists: α,β-methylene ATP (α,β-meATP) and β,γ-methylene ATP (β,γ-meATP). Cortical blood flow (CBF) was estimated by laser Doppler flux during intrarenal artery infusion of β,γ-meATP (20 nmol (kg min)(-1) , v = 2 μL min(-1)). Influence of α,β-meATP and β,γ-meATP on the activity of Na-K-ATPase was investigated in isolated proximal tubules. RESULTS Intravenous infusion of β,γ-meATP resulted in a marked, progressively increasing diuresis and this effect was accompanied by a progressive increase in the sodium excretion rate. The glomerular filtration rate was unaffected. The effects of β,γ-meATP were abolished by P2 receptor antagonist PPADS (70 nmol (kg min)(-1)). CBF increased by 16 ± 2% during renal artery infusion of β,γ-meATP. Furthermore, α,β-meATP and β,γ-meATP increased 1.5-fold lithium clearance (C(Li)). Sodium excretion, expressed as a fraction of the distal delivery (C(Na) C(Li) (-1)), increased 1.5-fold during infusion of α,β-meATP or β,γ-meATP. Both agonists at 10(-6) (M) produced a statistical significant decrement in the ouabain-sensitive ATPase activity about 16-20% and these effects were blocked in the presence of PPADS. CONCLUSION Activation of P2X receptors increased renal sodium and water excretion. Mechanistically, P2X agonists increased renal perfusion and inhibited sodium reabsorption via an Na-K-ATPase-dependent mechanism.
Collapse
Affiliation(s)
- M Jankowski
- Department of Therapy Monitoring and Pharmacogenetics, Medical University of Gdansk, Poland.
| | | | | | | | | |
Collapse
|
73
|
Jankowski M, Danalache BA, Gutkowska J. OXYTOCIN ROLE IN THE EMBRYONAL DEVELOPMENT OF THE HEART. J Hypertens 2011. [DOI: 10.1097/00004872-201106001-00059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
74
|
Undas A, Jankowski M, Kaczmarek P, Sladek K, Brummel-Ziedins K. Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition. Thromb Res 2011; 128:e24-8. [PMID: 21624643 DOI: 10.1016/j.thromres.2011.05.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2011] [Revised: 04/12/2011] [Accepted: 05/02/2011] [Indexed: 10/18/2022]
Abstract
BACKGROUND Chronic obstructive pulmonary disease (COPD) is associated with an increased risk for thromboembolic events. We investigated thrombin generation profiles in COPD patients and their dependence on plasma factor/inhibitor composition. METHODS Factors (f) (fII, fV, fVII, fVIII, fIX, fX), antithrombin, protein C (PC) and free tissue factor pathway inhibitor (fTFPI) from 60 COPD patients (aged 64.2 ± 10.1 years; a mean forced expiratory volume in 1 second [FEV(1)], 55.6 ± 15.8% of predicted values) were compared with those for 43 controls matched for age, sex, weight and smoking. Patients receiving anticoagulation were excluded. Using each individual's plasma coagulation protein composition, tissue factor-initiated thrombin generation was assessed computationally. RESULTS COPD patients had higher fII (115 ± 16 vs 102 ± 10%, p < 0.0001), fV (114 ± 19 vs 102 ± 12%, p = 0.0002), fVII (111 ± 15 vs 102 ± 17%, p = 0.002), fVIII (170 ± 34 vs 115 ± 27%, p < 0.0001), and fIX (119 ± 21 vs 107 ± 17%, p = 0.003), and lower fTFPI (17.7 ± 3.2 vs 18.9 ± 3.2 ng/ml, p = 0.047) compared with controls, while fX, antithrombin, and PC were similar in both groups. Computational thrombin generation profiles showed that compared with controls, COPD patients had higher maximum thrombin levels (+28.3%, p < 0.0001), rates of thrombin generation (+46.1%, p < 0.0001) and total thrombin formation (+14.4%, p < 0.001), together with shorter initiation phase of thrombin generation (p < 0.0001) and the time to maximum thrombin levels (p < 0.0001). Thrombin generation profiles in COPD patients can be normalized via correction of fII, fVIII , fIX and TFPI. The severity of COPD and inflammatory markers were not associated with thrombin generation profiles. CONCLUSIONS Prothrombotic phenotype in COPD patients is largely driven by increased prothrombin, fVIII, fIX, and lower fTFPI.
Collapse
Affiliation(s)
- Anetta Undas
- Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
| | | | | | | | | |
Collapse
|
75
|
Dakka Y, Warra N, Albadareen RJ, Jankowski M, Silver B. Headache rate and cost of care following lumbar puncture at a single tertiary care hospital. Neurology 2011; 77:71-4. [DOI: 10.1212/wnl.0b013e318220abc0] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
76
|
Rybicki B, Mitrache N, Do K, Jankowski M, Tang D, Rundle A, Bock C, Beebe-Dimmer J, Belinsky S. Methylation of Retinoic Acid Receptor, Beta (RARB) Gene Increases Risk for Prostate Cancer in African-American Men. Cancer Epidemiol Biomarkers Prev 2011. [DOI: 10.1158/1055-9965.epi-11-0091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
DNA methylation is an indicator of the initiation of prostate carcinogenesis and as such has utility as a marker of risk in pathologically negative prostate tissue samples. We conducted a matched case-control study nested in a historical cohort of over 6,000 men with pathologically benign prostate specimens identified between January 1991 and November 2002 with no previous history of prostate cancer. Eligible cases were diagnosed with prostate cancer at least one year after cohort entry. Controls were selected through incidence density sampling and matched to cases on date and age at cohort entry, race, and type of specimen. In 310 matched prostate cancer case-control pairs (65% white; 35% African American), we assayed the DNA of the benign prostate specimen for presence of methylation in a five-gene panel (APC, RARB, CCND2, RASSF1, MGMT) and then estimated the risk of developing prostate cancer associated with methylation at each gene for the whole sample and stratified by race. Overall, methylation of RARB had the strongest association with prostate cancer risk (HR = 1.94; 95% CI = 1.30 – 2.91). In race-stratified analyses, the majority of the increased risk associated with RARB was found in the African-American sample (HR = 3.40; 95% CI = 1.68–6.88). In addition, APC was also associated with increased risk for prostate cancer in the African-American sample (HR = 2.17; 95% CI = 1.09–4.29). In a model that included both genes, only RARB remained statistically significantly associated with prostate cancer (HR = 3.14; 95% CI = 1.54–6.44). In whites, methylation was not associated with prostate cancer for any of the five genes assayed. In summary, positive methylation status at RARB and APC in pathologically benign prostate is associated with significant increased risk for subsequent prostate cancer, but primarily in African-American men. Whether this race-specific risk is due to racial differences in environmental stimuli and/or biology is unclear, but further study of DNA methylation in the earliest stages of prostate carcinogenesis may help explain the disproportionate burden of this disease among African-American men.
Collapse
|
77
|
Heather N, Partington S, Partington E, Longstaff F, Allsop S, Jankowski M, Wareham H, St Clair Gibson A. Alcohol Use Disorders and Hazardous Drinking among Undergraduates at English Universities. Alcohol Alcohol 2011; 46:270-7. [DOI: 10.1093/alcalc/agr024] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
78
|
Ali H, Hensley Alford S, Saltzgaber J, Jankowski M, Ruszkowski S, Zarbo A. P232 The role of preoperative MRI in influencing the surgical decision making, a retrospective look at the experience of a large academic hospital in the face of a rising mastectomy rates. Breast 2011. [DOI: 10.1016/s0960-9776(11)70178-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
79
|
Jankowski M, Undas A, Kaczmarek P, Butenas S. Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation. Thromb Res 2011; 127:242-6. [PMID: 21236471 PMCID: PMC3042502 DOI: 10.1016/j.thromres.2010.11.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2010] [Revised: 10/01/2010] [Accepted: 11/02/2010] [Indexed: 11/18/2022]
Abstract
INTRODUCTION Increased cardiovascular mortality and risk of venous thromboembolism are serious extra-pulmonary complications of chronic obstructive pulmonary disease (COPD). Previously, circulating active tissue factor (TF) and factor XIa (FXIa) have been reported to be associated with acute coronary syndromes. OBJECTIVE To measure plasma FXIa and active TF, prothrombin fragment 1.2 (F1.2), and markers of systemic inflammation (C-reactive protein [CRP], interleukin-6 [IL-6], tumor necrosis factor α [TNFα] and matrix metalloproteinase 9 [MMP-9]) in 60 patients with documented stable COPD free of previous thromboembolic events. METHODS In-house clotting assays using inhibitory monoclonal antibodies against FXIa and TF. RESULTS FXIa was detected in 9 (15%) and TF activity in 7 (11.7%) COPD patients. Subjects positive for FXIa and/or TF (n=10; 16.7%) had higher F1.2 (median [interquartile range], 398 [216] vs 192 [42] pM, p<0.000001), fibrinogen (5.58 [2.01] vs 3.97 [2.47] g/L, p=0.0007), CRP (14.75 [1.20] vs 1.88 [2.95] mg/L, p<0.000001), IL-6 (8.14 [4.74] vs 2.45 [2.24] pg/mL, p=0.00002), and right ventricular systolic pressure (47 [15] vs 38 [12] mmHg, p=0.023), and lower vital capacity (66 [15] vs 80 [17] % predicted, p=0.04) than COPD patients without detectable FXIa and TF. COPD severity was not associated with the presence of circulating FXIa and active TF. CONCLUSIONS This is the first study to show that active FXIa and TF are present in stable COPD patients, who exhibit enhanced systemic inflammation and thrombin generation. Our findings suggest a new prothrombotic mechanism which might contribute to elevated risk of thromboembolic complications in COPD.
Collapse
Affiliation(s)
- Milosz Jankowski
- Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
| | - Anetta Undas
- Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
- Institute of Cardiology, Jagiellonian University School of Medicine, Krakow, Poland
| | - Przemyslaw Kaczmarek
- Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
| | - Saulius Butenas
- Department of Biochemistry, University of Vermont, Burlington, VT, USA
| |
Collapse
|
80
|
Broderick TL, Wang Y, Gutkowska J, Wang D, Jankowski M. Downregulation of oxytocin receptors in right ventricle of rats with monocrotaline-induced pulmonary hypertension. Acta Physiol (Oxf) 2010; 200:147-58. [PMID: 20377540 DOI: 10.1111/j.1748-1716.2010.02134.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
AIM pulmonary hypertension (PH) in the rat leads to right ventricular (RV) hypertrophy, inflammation and increased natriuretic peptide (NP) levels in plasma and RV. Because the release of nitric oxide (NO) and atrial natriuretic peptide (ANP) is a function of the oxytocin receptor (OTR), we examined the effect of PH on gene and protein expression of OTR, NP (A, atrial; B, brain) and receptors (NPRs), nitric oxide synthases (NOS), interleukin (IL)-1β, IL-6 and tumour necrosis factor-α in the hypertrophied RV in a model of PH. METHODS RV hypertrophy was induced in male Sprague-Dawley rats with monocrotaline (MCT; 60 mg kg(-1) ) and was confirmed by the presence of an increased RV weight and RV-to-[left ventricle (LV) and septum] ratio. RESULTS in the RV of MCT-treated rats, a approximately 40% reduction in OTR mRNA and protein was observed compared with the RV of control rats. This reduction was associated with increased transcripts of ANP and BNP in both ventricles and a corresponding increase in NP receptor mRNA expression for receptors A, B and C. Protein expression of inducible NOS was increased in the RV, whereas endothelial NOS transcripts were increased only in the LV of MCT-treated rats. In the RV of MCT-treated rats, downregulation of OTR was also associated with increased mRNA expression of IL-1β and IL-6. CONCLUSION our results show that downregulation of the OTR in the RV of MCT-treated rats is associated with increased expression of NP and their receptors as well as IL-1β and IL-6. This reduction in OTR in RV myocardium may have an impact on cardiac function in the MCT-induced model of PH.
Collapse
Affiliation(s)
- T L Broderick
- Laboratory of Diabetes and Exercise Metabolism, Departmentof Physiology, MidwesternUniversity, AZ 85308, USA.
| | | | | | | | | |
Collapse
|
81
|
Abstract
SUMMARY ReFacto Antihemophilic Factor is a second-generation antihaemophilia A product manufactured using a process that includes therapeutic grade human serum albumin (HSA) in the cell culture medium, but is formulated without HSA as a stabilizer. Even though this second-generation antihaemophilia product has a good safety profile, a programme was implemented to eliminate all animal- and human-derived raw materials from the production process, thus producing a third-generation product. To that end, HSA has been removed from the master and working cell banks and from the culture medium. The hybridoma-derived monoclonal antibody formerly used in the purification process has been replaced by a chemically synthesized affinity peptide, and a virus-retaining filtration step has been added to enhance the clearance of large viruses, such as retroviruses. The purification process has been validated for the removal of a panel of model viruses and provides significant clearance of all viruses tested. Host cell- and process-derived impurity removal validations also were conducted, including host cell DNA and protein, in addition to the affinity peptide. Compared with the product manufactured according to the original process, these changes had no detectable effect on the structural integrity, stability or clinical efficacy of this antihaemophilia A product. The product produced by the improved manufacturing process is named Xyntha/ReFacto AF.
Collapse
Affiliation(s)
- B Kelley
- Process Development, Genentech, Inc, 1 DNA Way, South San Francisco, CA, USA
| | | | | |
Collapse
|
82
|
Ignatowska-Jankowska B, Jankowski M, Glac W, Swiergel AH. Cannabidiol-induced lymphopenia does not involve NKT and NK cells. J Physiol Pharmacol 2009; 60 Suppl 3:99-103. [PMID: 19996489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 11/06/2008] [Accepted: 02/02/2009] [Indexed: 05/28/2023]
Abstract
The major non-psychoactive compound of cannabis plant, cannabidiol, has been reported to be a promising therapeutic agent for many inflammatory, autoimmune and neurodegenerative diseases. In spite of growing interest in therapeutic use of cannabidiol very little is known about its influence on the immune system. Present study aimed to evaluate lymphocyte subsets distribution in peripheral blood after repeated, systemic administration of cannabidiol. Adult male Wistar rats received intraperitoneal injections of vehicle or cannabidiol at dose of 2.5 or 5 mg/kg/day, for 14 consecutive days. Blood samples were collected one hour after the last injection. Three-color immunofluorescent antibody staining procedure (CD3-FITC/CD45RA-PC7/CD161A-APC and CD3-FITC/CD4-PC7/CD8-APC) was used for determination of T, B, NK, NKT, T helper, and T cytotoxic lymphocyte subsets. Total leukocyte number and percentage numbers of leukocyte subpopulations were also assessed. Administration of cannabidiol at dose of 5 mg/kg caused a significant decrease in total leukocyte number and a significant fall in total numbers of T, B, and both T helper and T cytotoxic lymphocyte subsets. This immunosuppressive effect did not affect the total numbers of NK and NKT cells that are responsible for the primary, nonspecific antiviral and antitumor immune response. In contrast, administration of cannabidiol at dose of 2.5 mg/kg increased the total and percentage NKT cells numbers, and the percentage number of NK cells. The results suggest that repeated treatment with cannabidiol inhibits specific immunity by reduction of T, B, T cytotoxic, and T helper cell numbers, and may enhance nonspecific antiviral and antitumor immune response related to NK and NKT cells.
Collapse
|
83
|
Jaeschke R, Jankowski M, Brozek J, Antonelli M. How to develop guidelines for clinical practice. Minerva Anestesiol 2009; 75:504-508. [PMID: 19002086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Recent decades have seen an explosion of clinical practice guidelines documents developed to inform clinicians about the best options for managing treatment, with the explicit intent to influence behaviour. As our exposure to guidelines has increased it has become clear that the process of guideline development should follow specific rules in order to avoid disagreement, misunderstanding, misleading recommendations, and confusion. In this article, we review the approach to developing clinical practice guidelines suggested by an international Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) workgroup. This approach suggests several steps for guideline development: 1. determine the purpose, scope, and intended audience; 2. select the panel of guideline authors; 3. specify the main focused clinical questions that the recommendations will address; 4. decide on the relative importance of outcomes; 5. find and summarize the evidence supporting each recommendation; 6. determine the quality of the available evidence; 7. evaluate the balance of desirable and undesirable consequences for a particular course of action; 8. formulate recommendations, including their strenght; and 9. consider a system for subsequent guideline implementation and evaluation. We aim to help the readers of practice guidelines asses those guidelines' quality and validity, as well as to assist the authors of future guidelines in systematically generating clinical recommendations.
Collapse
Affiliation(s)
- R Jaeschke
- Department of Medicine, McMaster University, Hamilton, ON, L8P 3B6, Canada.
| | | | | | | |
Collapse
|
84
|
Abstract
e22073 Background: Diabetes mellitus (DM) is one of the common morbidities in United States. Insulin therapy has been frequently used in its treatment. Some studies have postulated that activation of Insulin and Insulin-like growth factor (IGF) pathway may contribute to cancer proliferation, growth and resistance to anticancer therapies. The impact of insulin on diabetic patients with non-small cell lung cancer (NSCLC) has not been reported. Methods: 1,233 patients with NSCLC diagnosed between January 1999 and December 2004 were identified from the Tumor Registry at Henry Ford Health System. Based on inclusion criteria, data from 1,206 patients were extracted from the electronic medical records. Statistical analyses were performed between insulin and non insulin users. Results: Out of 1,206 patients, 193 patients had NSCLC and DM. Data was available from 192 patients. Sixty (31.3%) were on insulin at the time of NSCLC diagnosis and defined as insulin users, while 132 were not on insulin and defined as non- users (68.7%). Demographics, co-morbidities, disease stage at diagnosis, therapeutic interventions, and laboratory values were analyzed for overall and cancer-specific survival. More insulin users (81%) than non-users (64%) presented with advanced disease (stage ≥ 3) at diagnosis (P=0.02). Although no significant difference of Hemoglobin A1c was observed, the median survival from all causes of death was 6.5 months for insulin-users versus 9.9 months for non-users (P=0.08). When survival time was calculated from cancer-specific death, the median survival between insulin and non-insulin users was 7.2 months versus 38.7 months, respectively (P=0.002), with a hazard ratio (HR) for insulin use equals 1.91. Results from our univariable and multivariable analyses will be presented at the ASCO annual meeting in detail. Conclusions: This data indicates that the use of insulin may adversely affect the biology and clinical course of NSCLC with a tendency of advanced disease stage at diagnosis and a shorter cancer-specific survival time. Prospective study of DM with NSCLC or other cancer diagnosis will improve our understanding of this potential adverse effect on cancer biology and provide scientific rational to target IGF-pathway especially in diabetic patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | | | - D. Wang
- Henry Ford Hospital, detroit, MI
| |
Collapse
|
85
|
Jankowski M. Purinergic regulation of glomerular microvasculature and tubular function. J Physiol Pharmacol 2008; 59 Suppl 9:121-135. [PMID: 19261976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 11/05/2008] [Accepted: 12/20/2008] [Indexed: 05/27/2023]
Abstract
Purinergic molecules: ATP, ADP and adenosine regulate physiological processes through activation of purinoceptors in the plasma membrane. Experimental evidence supports the view that purinergic molecules affect glomerular and tubular functions. Purinergic molecule-induced changes of tension of mesangial cells and/or podocytes may influence GFR by affecting the glomerular ultrafiltration coefficient. On the other hand, purinoceptors are crucial for electrolyte and fluid homeostasis by modulating activity of sodium-potassium-ATPase, voltage-independent or -dependent ion channels and cAMP-dependent water channels.
Collapse
Affiliation(s)
- M Jankowski
- Department of Therapy Monitoring and Pharmacogenetics, Medical University of Gdansk, Poland.
| |
Collapse
|
86
|
Jankowski M, Angielski S, Szczepańska-Konkel M. Dissociation between the effects of P1, P4-diadenosine tetraphosphate (Ap4A) on renal haemodynamics and tubular function in anaesthetized rats. J Physiol Pharmacol 2008; 59:129-137. [PMID: 18441393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 07/03/2007] [Accepted: 01/22/2008] [Indexed: 05/26/2023]
Abstract
Previous studies from our laboratory have reported a marked reduction in glomerular filtration rate (GFR) and sodium reabsorption in renal proximal tubule during intravenous infusion of P(1),P(4)-diadenosine tetraphosphate (Ap(4)A) at dose of 1.0 micromol/kg + 10 nmol/kg/min (i.v., injection followed by infusion) in anaesthetized Wistar rats. In the present study, the changes of GFR and urine sodium excretion were investigated in response to systemic infusion of Ap(4)A at different doses. Ap(4)A at dose of 0.1 micromol/kg + 1.0 nmol/kg/min did not change GFR and sodium urinary excretion whereas 2-fold higher dose produced significant (3.4-fold) increase in sodium excretion without changes in GFR. Significant but transient reduction in GFR by approximately 21% was observed during infusion of Ap(4)A at dose of 0.5 micromol/kg + 5.0 nmol/kg/min. Higher doses of Ap(4)A (1.0 micromol/kg + 10 nmol/kg/min and 2.0 micromol/kg + 20 nmol/kg/min) reduction in GFR and marked natriuresis. Our results suggest that tubular sodium transport systems are more sensitive to Ap(4)A than systems involved in GFR regulation.
Collapse
Affiliation(s)
- M Jankowski
- Department of Monitoring Therapy and Pharmacogenetics, Medical University of Gdańsk, Poland.
| | | | | |
Collapse
|
87
|
Trojniar W, Plucińska K, Ignatowska-Jankowska B, Jankowski M. Damage to the nucleus accumbens shell but not core impairs ventral tegmental area stimulation-induced feeding. J Physiol Pharmacol 2007; 58 Suppl 3:63-71. [PMID: 17901583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 06/16/2007] [Accepted: 08/05/2007] [Indexed: 05/17/2023]
Abstract
Food intake is regulated not only by homeostatic requirements but also by emotional factors (e.g. palatability of food, alleviation of emotional tension etc.). The nucleus accumbens (Acb) is a part of the mesolimbic dopaminergic system which is responsible for a positive emotional aspect of various homeostasis-relevant stimuli. In the present work, we tested the Acb involvement in feeding behaviour using an experimental paradigm specifically designed to assess motivational vs motor aspect of food ingestion. In rats, feeding was evoked by electrical stimulation of the midbrain ventral tegmental area (a somatodendritic region of mesolimbic system) and assessed quantitatively with the use of the latency to feed/stimulation frequency curve-shift paradigm before and after electrolytic lesion of Acb. An impairment of stimulation-induced feeding manifesting as an elevation of the reaction threshold and a rightward, parallel shift of the stimulation frequency/reaction latency curve in the range of frequency which is sensitive to motivational aspects of food occurred after lesions localized mainly in the Acb shell. The lesions situated mainly in the Acb core were ineffective. The results obtained indicate that the Acb shell connected with the limbic system but not the motor-related Acb core affects motivational aspects of feeding behaviour.
Collapse
Affiliation(s)
- W Trojniar
- Department of Animal Physiology, University of Gdańsk, Gdańsk, Poland.
| | | | | | | |
Collapse
|
88
|
Hanbali AS, Wang D, Jankowski M, Urbaez E, Syed A, Farhan S. The use of statins may prolong survival of non-small cell lung cancer patients: Final update from 1,205 cases. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7638 Background: Hypercholesterolemia is one of the most common morbidities in United States. Statins have been proven as effective cholesterol-lowering agents and have been widely used in this country. They have been reported reducing the incidence and risk of various cancer types. However, the impact of using statins on the survival of 407 patients with diagnosed non-small cell lung cancer (NSCLC) was initially reported (Wang, et al. Abstract #7149, ASCO Meeting 2006). Methods: 1,233 patients with diagnosed non-small cell lung cancer were identified from the Tumor Registry at Henry Ford Health System between January 1999 and December 2004. The data from 1,206 patients were extracted from their available electronic medical records. Statistical analyses were performed and stratified for statin users versus non statin users. Results: Data from 1,205 eligible patients were included in this updated report. There were 391 patients with hypercholesterolemia, 250 of them were statin users at the time of their non-small cell lung cancer diagnosis. Average age was 68 (range 46–90) years for statin users and 65.9 (range 29–94) years for non statin users. Overall median survival of 1,205 subjects was 9.85 months. After stratifying for statin use, the median survival of statin users was 13.9 (95% C.I. 9.9 - 17.4) months while the median survival of non statin users was 9.6 (95% C.I. 8.1 - 10.4) months, with a P value of 0.0001. After having several prognostic variables (age, stage, co-morbids, other cancers, performance status, anti-cancer therapies, and serum albumin, etc.) adjusted, statin use still demonstrated protection from death with a hazard ratio of 0.74 (95% C.I. 0.59 - 0.95, P=0.017). Conclusion: The trend of survival benefit from NSCLC among statin users was shown in our previous report and it has maintained with further enhanced statistical significance in this update. Though statin use will unlikely become an independent anti-cancer regimen by itself, the choice of continuation of statin among NSCLC patients may still provide survival benefit to this population. The favorable impact of statin use on NSCLC patients is intriguing; a prospective study of co-morbidity management with statins in patients with non-small cell lung cancer is warranted. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. S. Hanbali
- Henry Ford Hosp, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - D. Wang
- Henry Ford Hosp, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - M. Jankowski
- Henry Ford Hosp, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - E. Urbaez
- Henry Ford Hosp, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - A. Syed
- Henry Ford Hosp, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - S. Farhan
- Henry Ford Hosp, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| |
Collapse
|
89
|
Wang D, Hanbali A, Jankowski M, Duran EU, Syed A, Farhan S, Chapman R. The use of statins may prolong survival of non-small cell lung cancer patients. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7149] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7149 Background: Hypercholesterolemia is one of the most common morbidities in United States. Statins have been proven as effective cholesterol-lowering agents and have been widely used in this country. They have been reported reducing the incidence and risk of various cancer types. However, the impact of using statins on the survival of patients with diagnosed non-small cell lung cancer is unknown. Methods: Ongoing retrospective study involves a cohort of 1,233 patients with diagnosed non-small cell lung cancer. Patients were identified from the Tumor Registry at Henry Ford Health System between January 1999 and December 2004. To date, the electronic medical records from 407 of the 1,233 cases were reviewed. Statistical analyses were performed and stratified for statin users versus non statin users. Results: Data from 407 patients were included in this analysis. There were 109 patients with hypercholesterolemia, 54 of them were statin users at the time of their non-small cell lung cancer diagnosis. Average age was 70 (range 46–85) years for statin users and 65 (range 29–93) years for non statin users. Median survival of 407 subjects was 9.82 months. After stratifying for statin use, the median survival of statin users was 12.38 months while the median survival of non statin users was 9.75 months, with a p value of 0.012. Conclusion: Though small sample size, this study is the first time ever suggesting a possible survival benefit of statin use in patients with non-small cell lung cancer who have received their standard anti-tumor regimens. Other variables that may contribute to this result will be further clarified and discussed after completing the data collection and analysis of this entire cohort. Based on our preliminary result, a prospective study of co-morbidity management with statins in patients with non-small cell lung cancer is warranted. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Wang
- Karmanos, Detroit, MI; Henry Ford Health System, Detroit, MI
| | - A. Hanbali
- Karmanos, Detroit, MI; Henry Ford Health System, Detroit, MI
| | - M. Jankowski
- Karmanos, Detroit, MI; Henry Ford Health System, Detroit, MI
| | - E. U. Duran
- Karmanos, Detroit, MI; Henry Ford Health System, Detroit, MI
| | - A. Syed
- Karmanos, Detroit, MI; Henry Ford Health System, Detroit, MI
| | - S. Farhan
- Karmanos, Detroit, MI; Henry Ford Health System, Detroit, MI
| | - R. Chapman
- Karmanos, Detroit, MI; Henry Ford Health System, Detroit, MI
| |
Collapse
|
90
|
Hanbali AS, Urbaez Duran E, Wang D, Jankowski M, Syed A, Farhan S, Chapman R. The use of statins and the effect on survival in patients with small cell lung cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17121] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17121 Background: Hypercholesterolemia is one of the most common morbidities in United States. Statins have been proven as effective cholesterol-lowering agents and have been widely used in this country. They have been reported reducing the incidence and risk of various cancer types. However, the impact of using statins on the survival of patients with diagnosed small cell lung cancer is unknown. Methods: A retrospective study involved a cohort of 282 patients with diagnosed small cell lung cancer. Patients were identified from the Tumor Registry at Henry Ford Health System between January 1995 and December 2002. Electronic medical records of these patients were reviewed. Statistical analyses were performed and stratified for statin users versus non statin users. Results: Out of 282 patients, there were 73 patients with hypercholesterolemia, 37 of them were statin users at the time of their small cell lung cancer diagnosis. Average age was 65 (range 34–87) years for non statin users and 69 (range 52–85) years for statin users. Median survival of 282 subjects was 7.37 months. After stratifying for statin use, the median survival of statin users was 8.66 months while the median survival of non statin users was 7.17 months (p = 0.29). Conclusion: Though slightly prolonged median survival in statin-users was observed, no survival benefit is demonstrated from this patient population. Factors that may have contributed to this result will be further discussed. With the trend of an increase in median survival among statin users, whenever possible, continuation of statins as co-morbidity management may still benefit patients with small cell lung cancer, during their receiving standard anti-tumor therapies. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. S. Hanbali
- Henry Ford Hospital, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - E. Urbaez Duran
- Henry Ford Hospital, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - D. Wang
- Henry Ford Hospital, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - M. Jankowski
- Henry Ford Hospital, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - A. Syed
- Henry Ford Hospital, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - S. Farhan
- Henry Ford Hospital, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| | - R. Chapman
- Henry Ford Hospital, Detroit, MI; Karmanos Cancer Institute, Detroit, MI
| |
Collapse
|
91
|
Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006; 26:1397-404. [PMID: 16574890 DOI: 10.1161/01.atv.0000219688.43572.75] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
OBJECTIVE Homocysteine (Hcy) is a risk factor for thrombosis. We investigated a hypothesis that the clot permeability and its resistance to fibrinolysis is associated with plasma total Hcy (tHcy) in human subjects. METHODS AND RESULTS We studied healthy men not taking any medication (n=76), male patients with advanced coronary artery disease (CAD) taking low-dose aspirin (n=33), men with diabetes mellitus diagnosed recently (median hemoglobin A(1c) 7.65%; n=16), and patients with isolated hypercholesterolemia (>7.0 mmol/L; n=15). We assessed clot permeability and turbidimetric lysis time as the determinants of fibrin clot structure. In a regression model, including age and fibrinogen, plasma tHcy was an independent predictor of clot permeation and fibrinolysis time in healthy subjects (R2=0.88, P<0.0001 and R2=0.54, P<0.0001, respectively). In CAD patients, tHcy and fibrinogen were stronger predictors of the permeation coefficient (R2=0.84; P<0.0001) than was fibrinogen alone (R2=0.66; P<0.0001), whereas tHcy was the only predictor of lysis time (R2=0.69; P<0.0001). Elevated tHcy levels observed after methionine load were not associated with any of the fibrin clot properties. In patients with diabetes or hypercholesterolemia, the influence of Hcy on permeation and, to a lesser extent, on the lysis time was obscured by dominant effects of glucose and cholesterol. In 20 asymptomatic men with hyperhomocysteinemia treated with folic acid, reduction in tHcy levels resulted in increased clot permeability (P=0.0002) and shorter lysis time (P<0.0001). CONCLUSIONS Our results indicate that plasma tHcy predicts clot permeation and susceptibility to fibrinolysis in healthy men and CAD patients. Our data are consistent with a mechanism of thrombosis in hyperhomocysteinemia, which involves modification of fibrinogen by Hcy-thiolactone.
Collapse
Affiliation(s)
- Anetta Undas
- Institute of Cardiology, Jagiellonian University School of Medicine, Krakow, Poland
| | | | | | | | | | | |
Collapse
|
92
|
Arnout J, Jankowski M. Understanding the antiphospholipid syndrome and its treatment. Curr Hematol Rep 2005; 4:385-90. [PMID: 16131440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
The antiphospholipid syndrome (APS) is a clinicopathologic disorder characterized by the persistent presence of anticardiolipin antibodies, lupus anticoagulants, or both in the plasma of patients with arterial or venous thrombosis or obstetric complications. The antiphospholipid antibodies involved in this syndrome have a relatively weak affinity for phospholipid-binding proteins such as b(2) glycoprotein I and prothrombin. In certain conditions they form bivalent antibody-protein complexes that bind with a relatively high affinity to negatively charged phospholipid surfaces. Evidence is accumulating for a pathogenetic role of antiphospholipid antibodies via interference with surface-mediated anticoagulant and procoagulant processes. The syndrome is characterized by the recurrence of thrombotic and obstetric complications. Retrospective studies have suggested that patients with APS and thrombosis need a high-intensity anticoagulant treatment. A few small prospective studies support treatment with a targeted INR of 2 to 3.
Collapse
Affiliation(s)
- Jef Arnout
- Center for Molecular and Vascular Biology, University of Leuven, Herestraat 49, B-3000 Leuven, Belgium.
| | | |
Collapse
|
93
|
van Bemmelen MXP, Szczepańska-Konkel M, Jastorff B, Jankowski M, Angielski S. Effect of cAMP analogues on glomerular inulin space of isolated rats renal glomeruli. J Physiol Pharmacol 2005; 56:111-20. [PMID: 15795479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/26/2004] [Accepted: 01/11/2005] [Indexed: 05/02/2023]
Abstract
Cyclic AMP has been generally recognised as activator of cAMP-dependent protein kinases. However, there is little evidence about role of cAMP-dependent protein kinase (PKA), in particular izoenzymes PKA-I and PKA-II, in glomeruli contractility. We measured changes of glomerular inulin space (GIS) as a marker of its contractility in the presence of phosphodiesterase resistance cAMP analogues; activators and inhibitors of PKA. Activator of PKA i.e. (Sp) 8-Cl-cAMPS (0.1-100 microM) decreased GIS. (Rp) 8-Cl-cAMPS (0.1-100 microM), inhibitor of PKA, was ineffective but shifted concentration-response curve of (Sp) 8-Cl-cAMPS to right at 50 microM. Specific A site activation by N6-benzoyl-cAMP decreased GIS with maximum at 0.1 microM. Activation of B site by 8-aminobutyloamino-cAMP (0.1-100 microM) had no effect. However, specific activation of both sites on PKA-I or PKA-II by site-selective analogue pairs e.g. 8-aminobutyloamino-cAMP plus 8-piperidino-cAMP or N6-benzoyl-cAMP plus 8-piperidino-cAMP respectively, significantly increased sensitivity of glomeruli to analogues. Our data suggest that activation of PKA-I or PKA-II might have an important role in the regulation of glomerular contractility.
Collapse
Affiliation(s)
- M X P van Bemmelen
- Institute of Pharmacology and Toxicology, Lausanne University, Switzerland
| | | | | | | | | |
Collapse
|
94
|
Abstract
Cyclic guanosine monophosphate (cGMP), which is implicated in cardiac cell growth and function, is synthesized by cytoplasmic soluble guanylyl cyclase (GC) stimulated via nitric oxide (NO) and by particulate membrane-bound GC activated via natriuretic peptides. We investigated possible cGMP elevation in the left ventricle (LV) of rats developing physiologic LV hypertrophy during gestation. Furthermore, expression of estrogen receptors (ER) and oxytocin receptors (OTR) was evaluated because their activation stimulates NO and atrial natriuretic peptide (ANP) release from the heart. Compared with nonpregnant controls, Sprague-Dawley rats on day 7 of gestation had similar heart weights, but, on days 14 and 21, ventricular mass increased by 12% and 28% respectively (P< 0.05). LV cGMP concentration was elevated at day 14 of gestation (3.25 +/- 0.12 vs 4.65 +/- 0.17 pmol/g wet weight, P< 0.01) but decreased at day 21 (2.45 +/- 0.09 pmol/g, P< 0.05) to increase again on postpartum day 1 (6.01 +/- 0.15 pmol/g) and day 4 (9.21 +/- 1.79 pmol/g). Changes in endothelial nitric oxide synthase (eNOS), inducible NOS (iNOS), OTR and ERalpha, but not ERbeta, proteins paralleled the pregnancy-related cGMP changes in the LV. In contrast, ANP mRNA of the LV remained at control level throughout gestation but increased postpartum, whereas brain natriuretic peptide (BNP) expression declined at term and increased postpartum. The particulate GC natriuretic peptide receptors (GC-A and GC-B) transcripts were already lower at day 14 of gestation. Natriuretic peptide clearance receptor (NPR-C) transcript was not altered on days 7 and 14, but increased at term. We conclude that cGMP concentration in the rat LV is influenced by both NOS and natriuretic peptide systems and may be involved in the changes of LV contractility and hypertrophy that occur during rat gestation.
Collapse
Affiliation(s)
- M Jankowski
- Laboratory of Cardiovascular Biochemistry, Centre de recherche, Centre hospitalier de l'Université de Montreal (CHUM) Montreal, Quebec, Canada.
| | | | | | | |
Collapse
|
95
|
Abstract
The cardiovascular and renal effects of a mu opioid agonist, [Dmt]DALDA, were studied in conscious Sprague-Dawley rats. During the first hour postinjection, [Dmt]DALDA (0.025-250 microg/rat, IV) evoked a dose-dependent diuresis. The dose of 2.5 microg increased urine volume from 1.0 +/- 0.2 to 3.4 +/- 0.3 mL/h (P < 0.001, n = 30), urinary excretion of sodium, potassium, and cGMP, and induced a mild antihypertensive effect. This dose increased cumulative 4-hour urine volume but significantly inhibited sodium and potassium excretions. The renal and cardiovascular effects were abolished by naloxone (4 mg/kg), but not by naloxonazine (35 mg/kg SC), a selective mu-1 receptor antagonist. Pretreatment with 8 mg/kg naloxone methiodide, an opioid antagonist with limited access to the brain, partially inhibited the renal effects of [Dmt]DALDA. Inhibition of nitric oxide synthases with L-NAME (1 mg/kg) had no effect on the renal and cardiovascular actions of [Dmt]DALDA. Plasma ANP and AVP, measured at 20 and 120 minutes after injection, were not altered by 2.5 and 25 microg [Dmt]DALDA. Therefore, [Dmt]DALDA evokes renal and cardiovascular effects that may primarily be mediated by central naloxonazine-insensitive mu opioid receptors (non-mu-1). These findings indicate that the central mu opioid system is involved in the regulatory mechanism of renal handling of sodium and water.
Collapse
Affiliation(s)
- J Gutkowska
- Laboratory of Cardiovascular Biochemistry, Centre Hospitalier de l'Université de Montréal-Hô-Dieu, Université de Montréal, Montréal, Québec, Canada.
| | | | | | | |
Collapse
|
96
|
Abstract
To better understand the role of atrial natriuretic peptide (ANP) in the central regulation of hydro-mineral homeostasis, we analysed its expression in rat hypothalamic neurones during gestation and postpartum. These physiological events are characterized by opposing body fluid regulations. Quantitative in situ hybridization analysis showed that starting from mid-pregnancy, ANP mRNA declined in neurones of the preoptic area, periventricular area, lateral hypothalamus and endorhinal nucleus, and remained low at postpartum. By contrast, magnocellular cells in the supraoptic nucleus (SON) showed four- and 10-fold more ANP mRNA in sections from preterm and postpartum rats, respectively, compared to nonpregnant controls (P < 0.001). Oxytocin mRNA paralleled ANP mRNA expression in the SON, whereas vasopressin mRNA rose in early pregnancy and declined thereafter. High hypothalamic ANP concentration at day 21 of gestation versus nonpregnant rats (3.1 +/- 0.5 versus 1.8 +/- 0.4 ng/mg protein, P < 0.05) suggested that ANP transcript accumulation in the SON is associated with increased utilization of the peptide. The elevation of hypothalamic ANP (two-fold) and ANP receptors by treatment of ovariectomized rats with 17beta-oestradiol (25 micro g/rat, 10 days) was abolished by coadministration of progesterone. Thus, we concluded that elevated oestradiol at term stimulates ANP synthesis and paracrine ANP activation in the hypothalamus. Overall, we provide experimental, anatomical and molecular evidence for ANP regulation in hypothalamic neurones at preterm and after 17beta-oestradiol stimulation. Our study supports the concept that ANP expressed in the SON acts as a peptidergic neurotransmitter involved in water and salt regulation during pregnancy and postpartum.
Collapse
Affiliation(s)
- M Jankowski
- Laboratory of Cardiovascular Biochemistry, Research Centre, Centre hospitalier de l'Université de Montréal (CHUM) - Hôtel-Dieu, Montreal, Quebec, Canada
| | | | | | | |
Collapse
|
97
|
|
98
|
Mukaddam-Daher S, Menaouar A, El-Ayoubi R, Gutkowska J, Jankowski M, Velliquette RA, Ernsberger P. Cardiac Effects of Moxonidine in Spontaneously Hypertensive Obese Rats. Ann N Y Acad Sci 2003; 1009:244-50. [PMID: 15028594 DOI: 10.1196/annals.1304.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Moxonidine, an imidazoline receptor agonist that acts centrally to inhibit sympathetic activity, has been shown to reduce effectively blood pressure, fasting insulin levels, and free fatty acids. In this study, we investigated the long-term effects of moxonidine treatment on cardiac natriuretic peptides (ANP and BNP) in Spontaneously Hypertensive Obese Rats (SHROBs), a rat model that resembles human Syndrome X. SHROBs expressing spontaneous hypertension, insulin resistance, and genetic obesity (weight 590 +/- 20 g, at 30 weeks) received moxonidine in chow at 4 mg/kg/day for 15 days. Moxonidine significantly reduced not only systolic blood pressure (187 +/- 6 versus 156 +/- 5 mm Hg, P < 0.05) but also plasma ANP (1595 +/- 371 versus 793 +/- 131 pg/mL, P < 0.05) and BNP (22 +/- 3 versus 14 +/- 1 pg/mL, P < 0.04), without influencing cardiac content of either peptide. Semi-quantitative PCR revealed that atrial ANPmRNA/GAPDHmRNA decreased to 39% 6 10% of pair-fed controls, P < 0.03. In left ventricles, moxonidine also decreased ANP mRNA to 69% +/- 7% and BNP mRNA to 74% +/- 6% of control, P < 0.02, but right ventricular ANP and BNP mRNA were not affected. These findings indicate that chronic inhibition of sympathetic activity with moxonidine in SHROB is associated with decreased ventricular natriuretic peptide transcription, consistent with the cardioprotective effects of moxonidine given the role of ANP and BNP as markers of cadiac disease. Moxonidine also improves the metabolic profile in these rats, thus it may be considered the drug of choice in treatment of metabolic syndrome X.
Collapse
Affiliation(s)
- S Mukaddam-Daher
- CHUM-Research Center, Universite de Montreal, Montreal, QC, Canada.
| | | | | | | | | | | | | |
Collapse
|
99
|
Szczepańska-Konkel M, Langner G, Bednarczuk G, Stiepanow-Trzeciak A, Jankowski M, Angielski S. Renal haemodynamics and natriuretic responses to intravenous administration of diadenosine tetraphosphate (Ap4A) and nicotinamide adenine dinucleotide (NAD) in rat. J Physiol Pharmacol 2003; 54:163-73. [PMID: 12832719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/05/2003] [Accepted: 04/24/2003] [Indexed: 03/03/2023]
Abstract
Effects of Ap4A and NAD--precursor of adenosine, on renal plasma flow (RPF), glomerular filtration rate (GFR) and urine excretion were determined in the anaesthetised rats. Infusion of Ap4A or NAD (i.v., bolus--1 micromol/kg followed by 10 nmol/min/kg) decreased RPF and GFR (by 30 and 40%, respectively). In spite of GFR reduction during Ap4A infusion, the significant increase in sodium excretion and urine flow was noticed: fractional sodium (FENa) and urine excretion (FEurine) rose 15-fold and 2.5-fold in comparison with the control value, respectively. In contrast to Ap4A, NAD-induced decrease in GFR was associated with parallel decrease in sodium and urine excretion, thus the FENa and FEurine did not significantly change. Pretreatment with adenosine deaminase (adenosine degrading enzyme, 2 U/min/kg) or theophylline (P1-receptors antagonist, 0.2 mmol/min/kg) ceased responses to NAD, whereas Ap4A-induced changes were not affected. Pre-treatment with suramin (P2-receptors antagonist, (i.v., bolus--12 mg/kg followed by 1.2 mg/min/kg) completely abolished the renal effects of Ap4A. We conclude that Ap4A may exert specific action on renal function. It acts different from NAD that modified renal function through its hydrolysis product--adenosine. Ap4A might reduce glomerular filtration rate and evoke natriuresis and diuresis, and its effects are probably mediated through stimulation of P2-receptors.
Collapse
Affiliation(s)
- M Szczepańska-Konkel
- Department of Clinical Chemistry, Medical Research Centre of the Polish Academy of Science, Gdańsk, Poland.
| | | | | | | | | | | |
Collapse
|
100
|
Jankowski M, Szczepańska-Konkel K, Kalinowski L, Angielski S. Involvement of Rho-kinase in P2Y-receptor-mediated contraction of renal glomeruli. Biochem Biophys Res Commun 2003; 302:855-9. [PMID: 12646249 DOI: 10.1016/s0006-291x(03)00272-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The involvement of Rho-kinase in P2Y-receptor induced contraction of isolated rat renal glomeruli was investigated. The contraction effects have been investigated based on changes in the intracapillary volume of isolated glomeruli. ATP was found to induce time- and concentration-dependent contraction of isolated glomeruli. Other tested nucleotides (ADP, UTP) and ATP analogues (beta,gamma-methylene-ATP, 2-methylothio-ATP) contracted glomeruli in similar magnitude whereas AMP had no effect. Furthermore, the contractive effect of ATP was prevented in the presence of an antagonist of P2Y-receptors, reactive blue 2. However, a selective antagonist of A1-receptors, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), had no effect. Contraction induced by ATP, ADP, and UTP, in contrast to 2-methylothio-ATP and beta,gamma-methylene-ATP, was prevented in the presence of Rho-kinase's inhibitor, (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide dihydrochloride monohydrate (Y-27632). These findings suggest the involvement of Rho-kinase pathways in P2Y-induced contraction of isolated glomeruli.
Collapse
Affiliation(s)
- M Jankowski
- Department of Clinical Biochemistry, Medical University of Gdańsk, Poland.
| | | | | | | |
Collapse
|